Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008975 | 0.81 | CPB2 (0.75) | CPB2FOLH1CPA3 | |
| SCHEMBL4013708 | 0.81 | CPB2 (0.56) | CPB2FOLH1CPA3 | |
| SCHEMBL4007106 | 0.75 | CPB2 (0.71) | CPB2FOLH1CPA3 | |
| SCHEMBL27517454 | 0.73 | CPB2 (0.33) | CPB2 | |
| SCHEMBL27667737 | 0.72 | CPB2 (0.56) | CPB2FOLH1CPA3 | |
| SCHEMBL4010501 | 0.71 | GABRP (0.55) | CPB2FOLH1CPA3 | |
| SCHEMBL12020098 | 0.70 | DHFR (0.41) | — | |
| SCHEMBL4005845 | 0.69 | CPB2 (0.55) | CPB2FOLH1CPA3 | |
| SCHEMBL27517453 | 0.68 | CPB2 (0.35) | CPB2 | |
| SCHEMBL4005849 | 0.66 | SMN1; SMN2 (0.47) | FOLH1CPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009082340-A1 | METHOD FOR MONITORING THE PROGRESSION OF FIBRINOLYSIS'646 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-7071175-B1 | Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1180098-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066557-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |